Log in

NASDAQ:ATRAAtara Biotherapeutics Stock Price, Forecast & News

$11.50
+0.26 (+2.31 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.15
Now: $11.50
$11.62
50-Day Range
$7.76
MA: $9.87
$14.93
52-Week Range
$4.52
Now: $11.50
$24.75
Volume1.83 million shs
Average Volume1.07 million shs
Market Capitalization$677.95 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Read More
Atara Biotherapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATRA
CUSIPN/A
Phone650-278-8930

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.29 per share

Profitability

Net Income$-290,980,000.00

Miscellaneous

Employees321
Market Cap$677.95 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

How has Atara Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATRA shares have increased by 15.5% and is now trading at $11.50. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Atara Biotherapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atara Biotherapeutics.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Atara Biotherapeutics.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics Inc (NASDAQ:ATRA) announced its earnings results on Wednesday, May, 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.41) by $0.21. View Atara Biotherapeutics' earnings history.

What price target have analysts set for ATRA?

9 Wall Street analysts have issued 1 year price targets for Atara Biotherapeutics' shares. Their forecasts range from $9.00 to $70.00. On average, they anticipate Atara Biotherapeutics' stock price to reach $29.38 in the next year. This suggests a possible upside of 155.4% from the stock's current price. View analysts' price targets for Atara Biotherapeutics.

Has Atara Biotherapeutics been receiving favorable news coverage?

News stories about ATRA stock have been trending very positive recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Atara Biotherapeutics earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutAtara Biotherapeutics.

Are investors shorting Atara Biotherapeutics?

Atara Biotherapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 11,980,000 shares, an increase of 17.1% from the April 30th total of 10,230,000 shares. Based on an average trading volume of 855,700 shares, the days-to-cover ratio is currently 14.0 days. Currently, 22.8% of the company's stock are short sold. View Atara Biotherapeutics' Current Options Chain.

Who are some of Atara Biotherapeutics' key competitors?

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include Crispr Therapeutics (CRSP), AbbVie (ABBV), Gilead Sciences (GILD), Micron Technology (MU), Amarin (AMRN), Editas Medicine (EDIT), Exelixis (EXEL), Karyopharm Therapeutics (KPTI), Advanced Micro Devices (AMD) and ImmunoGen (IMGN).

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the following people:
  • Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)
  • Mr. Utpal Koppikar, Chief Financial Officer (Age 49)
  • Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)
  • Ms. Mina Kim, Sr. VP of Corp. Strategy, Gen. Counsel & Sec. (Age 45)
  • Dr. Dietmar P. Berger M.D., Ph.D., Global Head of R&D (Age 56)

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (8.98%), Maverick Capital Ltd. (8.82%), BlackRock Inc. (7.74%), Morgan Stanley (5.87%), Morgan Stanley (5.87%) and Federated Hermes Inc. (4.90%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Eric Dobmeier, Isaac E Ciechanover, Joe Newell, Joel S Marcus and Utpal Koppikar. View institutional ownership trends for Atara Biotherapeutics.

Which major investors are selling Atara Biotherapeutics stock?

ATRA stock was sold by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Wasatch Advisors Inc., Two Sigma Investments LP, Wells Fargo & Company MN, AXA, UBS Group AG, BlackRock Inc., and Vident Investment Advisory LLC. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Isaac E Ciechanover, Joe Newell, and Utpal Koppikar. View insider buying and selling activity for Atara Biotherapeutics.

Which major investors are buying Atara Biotherapeutics stock?

ATRA stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Federated Hermes Inc., Morgan Stanley, Morgan Stanley, Maverick Capital Ltd., JPMorgan Chase & Co., FDx Advisors Inc., and FDx Advisors Inc.. Company insiders that have bought Atara Biotherapeutics stock in the last two years include Eric Dobmeier, and Utpal Koppikar. View insider buying and selling activity for Atara Biotherapeutics.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $11.50.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $677.95 million. The biotechnology company earns $-290,980,000.00 in net income (profit) each year or ($5.67) on an earnings per share basis. Atara Biotherapeutics employs 321 workers across the globe.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is www.atarabio.com.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.